Common Names: S-adenosyl-L-methionine, SAMe, Ademetionine, SAM-e, Adomet
Scientific Names: (2S)-2-Amino-4-[(S)-{[(2S,3S,4R,5R)-5-(4-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl}methylsulfaniumyl]butanoate
S-Adenosyl methionine (SAMe), also known as SAM, SAM-e, or AdoMet, plays a crucial role in the body as a cosubstrate involved in methyl group transfers, transsulfuration, and aminopropylation. Primarily produced and consumed in the liver, SAMe is integral to more than 40 methyl transfer reactions affecting nucleic acids, proteins, lipids, and secondary metabolites. Discovered in 1952 by Giulio Cantoni, it is synthesized from ATP and methionine. SAMe is vital for various biological processes including DNA, tRNA, and rRNA methylation, immune response, amino acid metabolism, and the biosynthesis of ethylene in plants.
In the SAM cycle, SAM-dependent methylases produce S-adenosyl homocysteine, which is hydrolyzed to homocysteine and adenosine, eventually recycling back to methionine and SAM. This cycle is crucial for maintaining proper metabolic function. SAMe acts as a methyl donor in the body and is involved in maintaining metabolic reactions. Lower levels of SAMe are linked to conditions like osteoarthritis and depression, where supplementation can be beneficial.
SAMe's side effects are uncommon, but in rare cases, it can induce mania, even in individuals without a history of this condition. While its benefits in diabetes are not as well established as in depression and osteoarthritis, SAMe is still considered a significant nutrient-like compound, regulated within a specific serum range and associated with adverse effects when this range is disturbed. Despite its potential benefits, the safety and efficacy of SAMe in treating various diseases requires further investigation through large-scale clinical trials.